Tyra Biosciences price target raised to $15 from $12 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Tyra Biosciences to $15 from $12 and keeps a Buy rating on the shares after the company announced TYRA-300 will be developed in achondroplasia.